Drugs that contain Simvastatin; Sitagliptin Phosphate

1. Drug name - JUVISYNC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(3 years from now)

CN1861077A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Oct, 2008

(13 years ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN100430397C MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN1832949A MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP1654263A1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B2 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1412357B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP1412357A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor Oct, 2026

(4 years from now)

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;EQ 50MG BASE TABLET;ORAL Discontinued
10MG;EQ 100MG BASE TABLET;ORAL Discontinued
20MG;EQ 50MG BASE TABLET;ORAL Discontinued
20MG;EQ 100MG BASE TABLET;ORAL Discontinued
40MG;EQ 50MG BASE TABLET;ORAL Discontinued
40MG;EQ 100MG BASE TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.